{"id":7706,"date":"2024-11-12T21:15:12","date_gmt":"2024-11-12T13:15:12","guid":{"rendered":"https:\/\/chimebiologics.com\/?p=7706"},"modified":"2025-06-16T15:42:24","modified_gmt":"2025-06-16T07:42:24","slug":"chime-biologics-and-waterstone-announce-a-strategic-partnership-to-empower-antibody-drug-conjugate-adc-development-and-manufacturing","status":"publish","type":"post","link":"https:\/\/chimebiologics.com\/ja\/chime-biologics-and-waterstone-announce-a-strategic-partnership-to-empower-antibody-drug-conjugate-adc-development-and-manufacturing\/","title":{"rendered":"(English) Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing"},"content":{"rendered":"<p class=\"qtranxs-available-languages-message qtranxs-available-languages-message-ja\">\u7533\u3057\u8a33\u3042\u308a\u307e\u305b\u3093\u3001\u3053\u306e\u30b3\u30f3\u30c6\u30f3\u30c4\u306f\u305f\u3060\u4eca\u3000<a href=\"https:\/\/chimebiologics.com\/en\/wp-json\/wp\/v2\/posts\/7706\" class=\"qtranxs-available-language-link qtranxs-available-language-link-en\" title=\"English\">English<\/a>\u3068 <a href=\"https:\/\/chimebiologics.com\/zh\/wp-json\/wp\/v2\/posts\/7706\" class=\"qtranxs-available-language-link qtranxs-available-language-link-zh\" title=\"\u4e2d\u6587\">\u4e2d\u6587<\/a>\u3000\u306e\u307f\u3067\u3059\u3002 For the sake of viewer convenience, the content is shown below in this site default language. You may click one of the links to switch the site language to another available language.<\/p><style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-iwqe2-97bb6aa3783a5420eb8a707e0ad897c8\">\n.flex_column.av-iwqe2-97bb6aa3783a5420eb8a707e0ad897c8{\n-webkit-border-radius:0px 0px 0px 0px;\n-moz-border-radius:0px 0px 0px 0px;\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div class='flex_column av-iwqe2-97bb6aa3783a5420eb8a707e0ad897c8 av_two_third  avia-builder-el-0  el_before_av_one_third  avia-builder-el-first  first flex_column_div av-zero-column-padding '     ><section  class='av_textblock_section av-k6j2pxor-09272cddfdcc1afe6211303b3b3d55e0'  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock'  itemprop=\"text\" ><div class=\"mceTemp\"><\/div>\n<p><\/p>\n<\/div><\/section><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-2d3l4o-9301d0cdc14489efa114080353995aa9\">\n.flex_column.av-2d3l4o-9301d0cdc14489efa114080353995aa9{\n-webkit-border-radius:0px 0px 0px 0px;\n-moz-border-radius:0px 0px 0px 0px;\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div class='flex_column av-2d3l4o-9301d0cdc14489efa114080353995aa9 av_one_third  avia-builder-el-2  el_after_av_two_third  el_before_av_one_full  flex_column_div av-zero-column-padding '     ><\/div><\/p>\n<div class='flex_column av-av_one_full-7714eba142aeda1f8b5272a3c372b279 av_one_full  avia-builder-el-3  el_after_av_one_third  avia-builder-el-last  first flex_column_div column-top-margin'     ><section  class='av_textblock_section av-mbstp8j3-2ebdb7490f97f9509c47e5e141ec9a3e'  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock'  itemprop=\"text\" ><p><\/p>\n<h1><strong>Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing<\/strong><\/h1>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-7715 aligncenter\" src=\"https:\/\/chimebiologics.com\/wp-content\/uploads\/2024\/11\/1112-\u5934\u56fe2.jpg\" alt=\"\" width=\"1080\" height=\"461\" srcset=\"https:\/\/chimebiologics.com\/wp-content\/uploads\/2024\/11\/1112-\u5934\u56fe2.jpg 1080w, https:\/\/chimebiologics.com\/wp-content\/uploads\/2024\/11\/1112-\u5934\u56fe2-300x128.jpg 300w, https:\/\/chimebiologics.com\/wp-content\/uploads\/2024\/11\/1112-\u5934\u56fe2-1030x440.jpg 1030w, https:\/\/chimebiologics.com\/wp-content\/uploads\/2024\/11\/1112-\u5934\u56fe2-768x328.jpg 768w, https:\/\/chimebiologics.com\/wp-content\/uploads\/2024\/11\/1112-\u5934\u56fe2-705x301.jpg 705w\" sizes=\"auto, (max-width: 1080px) 100vw, 1080px\" \/><\/p>\n<ul>\n<li><strong><em>Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry.<\/em><\/strong><\/li>\n<li><strong><em>Chime Biologics will leverage its CMC expertise in biologics to manage Antibody Intermediate, ADC Drug Substance and Drug Product, while Waterstone will supply Linker-payload.<\/em><\/strong><\/li>\n<\/ul>\n<p><strong>November 12, 2024, Wuhan, China<\/strong> \u2013 Chime Biologics, a leading global CDMO that enables its partners\u2019 success in biologics, and Waterstone, a reliable partner for its worldwide customers through continuous improvement and innovation to ensure high quality and sustainable service, today announced a strategic partnership aimed at providing integrated services for Antibody-Drug Conjugate (ADC) industry worldwide.<\/p>\n<p>Through\u00a0this\u00a0collaboration, Chime Biologics and Waterstone will offer a comprehensive solution to the ADC developers for IND-enabling and clinical studies. Leveraging its CMC expertise in biologics, Chime Biologics will manage Antibody Intermediate, ADC Drug Substance and Drug Product process development and cGMP manufacturing. Waterstone will supply Linker-payload, a critical intermediate in the ADC manufacturing process.<\/p>\n<p><strong>Dr. Faming Zhang, CEO of Waterstone<\/strong> commented, \"Our partnership with Chime Biologics is a significant milestone for Waterstone. Their expertise in antibody drug development and GMP manufacturing will be instrumental as we expand into global markets and advance our assets. We are excited about this collaboration, which provides a bright future for our company and for the broader ADC industry.\"<\/p>\n<p><strong>Dr. Jimmy Wei, President of Chime Biologics<\/strong>, added, \"We are thrilled to embark on this strategic collaboration with Waterstone. Currently, Chime Biologics has begun to undertake multiple ADC projects. This partnership will significantly advance our innovation and growth in the ADC field. We look forward to exploring the boundless possibilities of ADC together with Waterstone.\"<\/p>\n<p><strong>About Waterstone<\/strong><\/p>\n<p>Waterstone Pharmaceuticals was founded and managed by a dedicated professional team with decades of global pharmaceutical industrial experience. With a focus on R&amp;D and manufacturing of polymer drugs and high potency small molecules, the company specializes in polymer drugs, diabetes and ADC small molecule areas. Waterstone has established a long-term and stable cooperative relationship with well-known pharmaceutical companies around the world. The manufacturing site has been inspected by the FDA multiple times and provides a fully integrated CDMO\/MAH services from R&amp;D to commercial production. For more information, please visit: <a href=\"http:\/\/www.waterstonepharma.com\">www.waterstonepharma.com<\/a>.<\/p>\n<p><strong>About Chime Biologics<\/strong><\/p>\n<p>Chime Biologics is a global leading CDMO that has introduced the first modular biopharmaceutical plant KUBio in the world to empower its partners\u2019 success in biologics in the whole process from cell line development to commercial manufacturing. Relying on cell line development and advanced technology development from our Shanghai Innovation Center and proven success in IND-enabling through BLA filing at its Wuhan plant, Chime Biologics is providing a one-stop CMC solution for biopharmaceutical customers around the world. We share a common goal to make cutting-edge biomedicines affordable and accessible to all patients globally, fulfilling its commitment to human health. For more information, please visit: <a href=\"http:\/\/www.chimebiologics.com\" target=\"_blank\" rel=\"noopener\">www.chimebiologics.com<\/a>.<\/p>\n<p><\/p>\n<div class=\"mceTemp\"><\/div>\n<\/div><\/section><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":7715,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[46,52,51],"tags":[],"class_list":["post-7706","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-corporate-news","category-news","category-newsroom"],"_links":{"self":[{"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/posts\/7706","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/comments?post=7706"}],"version-history":[{"count":17,"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/posts\/7706\/revisions"}],"predecessor-version":[{"id":8776,"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/posts\/7706\/revisions\/8776"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/media\/7715"}],"wp:attachment":[{"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/media?parent=7706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/categories?post=7706"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/chimebiologics.com\/ja\/wp-json\/wp\/v2\/tags?post=7706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}